Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders
Berlin and Toronto, November 11, 2019 ATAI Life Sciences AG, a global biotech platform that
Social Comparisons: Effects on Mental Health
As a society becomes more and more unequal, status anxiety increases across all income deciles,
Gender Disparities and Mental Health Risk Factors
Gender greatly influences the power that males and females have over socio-economic factors that influence
Inequality: An overlooked contributor to mental health disorders (part 1)
Most people are aware of common risk factors for mental illness, such as genetics, adverse
The Power of Combining 5G and AI
Putting the two technologies together will change everything from drug making to brewing beer.
Can a Trip-Free Psychedelic Still Help People With Depression?
Psilocybin has shown promise for conditions like depression. Now, researchers are asking if the psychedelic experience is absolutely necessary to treat mental health.
Investors hope psychedelics are the new cannabis. Are they high?
In January atai Life Sciences, the German biotech company he founded last year, acquired a majority stake in Perception Neuroscience, a biopharmaceutical firm from New York which is developing a medication for pyschiatric conditions like depression from the drug, which is illegal in parts of the world.
ATAI Life Sciences Is Assembling a Mental-Health Drug Platform
A startup backed by $80 million from investors is striking deals with a range of drug companies in its bid to lead the next wave of mental-health treatments.
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space